Aura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc boosted its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 43.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 390,695 shares of the company's stock after acquiring an additional 118,000 shares during the period. Ensign Peak Advisors Inc owned about 0.78% of Aura Biosciences worth $3,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in AURA. BNP Paribas Financial Markets purchased a new stake in shares of Aura Biosciences during the 4th quarter worth $50,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Aura Biosciences during the fourth quarter valued at about $87,000. Harvest Investment Services LLC bought a new stake in shares of Aura Biosciences in the 4th quarter valued at about $133,000. AlphaQuest LLC purchased a new position in shares of Aura Biosciences in the 4th quarter worth approximately $136,000. Finally, Intech Investment Management LLC bought a new position in shares of Aura Biosciences during the 4th quarter worth approximately $172,000. Hedge funds and other institutional investors own 96.75% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on AURA shares. JMP Securities set a $19.00 price objective on Aura Biosciences in a report on Wednesday, March 26th. Citigroup reissued an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. Finally, HC Wainwright set a $25.00 price objective on shares of Aura Biosciences in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $22.75.

Insider Buying and Selling at Aura Biosciences

In other news, insider Conor Kilroy sold 7,162 shares of the company's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the sale, the insider now owns 179,313 shares of the company's stock, valued at $984,428.37. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.40% of the company's stock.

Aura Biosciences Trading Up 0.5%

AURA traded up $0.03 on Tuesday, reaching $5.95. The stock had a trading volume of 32,585 shares, compared to its average volume of 209,354. The business's 50-day moving average price is $5.88 and its two-hundred day moving average price is $7.49. The company has a market cap of $299.20 million, a P/E ratio of -3.42 and a beta of 0.43. Aura Biosciences, Inc. has a 12-month low of $4.35 and a 12-month high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.08). As a group, analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.